Abstract
Abstract Glioblastoma multiforme (GBM) are aggressive and malignant tumors that develop in the brain. These tumors are characterized by increased rates of proliferation and invasive migration as well as angiogenesis. To date few therapeutic options exist for the treatment and management of GBMs, therefore we decided to investigate the anti-oncogenic properties of extracts from the rosehip plant. Rosehip extracts have been used for centuries as alternative therapies. Currently, rosehip extracts are being used as over the counter supplements and recent studies demonstrate that it has an anti-tumor effect. Therefore, we tested the anti-migratory and antiproliferative capacity of extracts from the rosehip (Rosa canina) plant in GBM cell lines. Three human GBM cell lines, U-251 MG, U-1242MG and A-172, were treated with rosehip extracts (1 mg/mL - 25ng/mL) and demonstrated a decrease in cell proliferation. The rosehip extract-mediated decrease in cell proliferation was equal to the decrease of cell proliferation observed when U0126 (10µM), a know inhibitor of GBM cell proliferation was utilized. Utilizing a fluorescent-based labeling strategy (Live-Dead Assay), we examined whether rosehip extracts prevented cell proliferation by initiating apoptosis. Pretreatment of the GBM cells with rosehip extracts (1 mg/mL - 25ng/mL) induced the inhibition of cell proliferation without promoting apoptosis; whereas, cells treated with staurosporine (1 µM), a known inducer of apoptosis, showed an increase in cell apoptosis. Additional studies demonstrated that rosehip extracts prevent GBM cell proliferation by decreasing the active state of MAPK and AKT. Furthermore, rosehip extract-treated GBM cells also prevent cell migration by regulating actin remodeling. Taken together, these data suggest that rosehip extracts inhibit cell proliferation via a cytostatic mechanism that does not by induce apoptosis while also serving as a migration inhibiting agent. These data suggest that, rosehip extracts may serve as an alternative, or supplement, to current therapeutic regimens for GBMs. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1986. doi:1538-7445.AM2012-1986
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
